Company intelligence / Profile preview

oncoMASTER

Seoul, Seoul, South Koreaonco-master.com ↗

Ownership: Private
Development stage: Commercial

Overview

oncoMASTER has developed advanced AI algorithms that integrate multiomics and clinical real-world data to predict patient responses to cancer therapies. Their OCM series models are being clinically validated, with OCM-001 focused on predicting chemotherapy response in colorectal cancer and OCM-002 aimed at forecasting immunotherapy outcomes. The company is expanding through international collaborations, notably in the Middle East, to adapt its technology to diverse populations.

Therapeutic areas: Oncology
Modalities: Device (AI-powered clinical decision support system)Non-pharmacological therapy (predictive analytics for drug response)
Industry: Digital Health Medical Devices

Partnerships

Novo Genomics (Saudi Arabia) – collaboration for precision oncology research and S-MASTER project in Saudi Arabia

Beyond the preview

Go deeper on oncoMASTER.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oncoMASTER.

Explore the full profile